In vitro activity of tigecycline and 13 comparators against pathogens from a global population of intensive care patients in 2007
Abstract number: P684
Hackel M., Hoban D., Bouchillon S., Johnson B., Badal R., Johnson J., Dowzicky M.
Objectives: Tigecycline is a novel antimicrobial from a new class of compounds, the glycylcyclines, which has been shown to have potent broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections. The Tigecycline Evaluation Surveillance Trial (TEST), a global longitudinal surveillance study, surveyed the in vitro activity of tigecycline and 13 comparator compounds against pathogens from ICU patients from a global population during 2007.
Methods: A total of 14,113 clinical isolates from 386 testing sites in 49 countries were evaluated. Minimum Inhibitory Concentration (MICs) were determined by each site using common broth microdilution panels and interpreted according to CLSI and FDA guidelines.
Results: See the tables.
Conclusion: Tigecycline's in vitro activity was comparable to or greater than most commonly prescribed broad spectrum antimicrobials for all ICU bacterial study strains encountered. Tigecycline's inhibitory activity against Enterobacteriaceae, and Acinetobacter spp. was comparable to imipenem. Against Gram-positive organisms, tigecycline's MIC90 values of 0.25 mg/mL suggest that tigecycline may be an effective and reliable therapeutic option against these pathogens in an Intensive Care setting.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|